[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ulcer-healing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ulcer-healing":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100645178","topical-application-of-sucralfate-in-promoting-healing-of-esophageal-ulcers-after-esophageal-varices-ligation-a-randomized-controlled-trial-100645178",false,"NCT07679191","Topical Application of Sucralfate in Promoting Healing of Esophageal Ulcers After Esophageal Varices Ligation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* cirrhotic patients aged ≥ 18 years who accept endoscopy for esophageal variceal bleeding\n\nExclusion Criteria:\n\n* no need of endoscopic hemostasis\n* allergy to sucralfate\n* other etiology of bleeding than EV bleeding","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","Patients with EV bleeding often suffered from hematemesis, Tarry stool, and blood loss. Standard treatment for bleeding esophageal varices includes hemodynamic stabilization, pharmacological control, and endoscopic intervention. For endoscopic intervention, endoscopic variceal ligation (EVL) is the first-line therapy with 95% initial hemostasis success rate. However, after variceal ligation, esophageal ulcers form 3 days later. These ulcers expose underlying vessels in friable esophageal mucosa, exacerbated by portal hypertension and coagulopathy in cirrhosis patients. Bleeding peaks around day 5-10 when bands detach. Among these patients, 7-9% of patients experience recurrent bleeding as a result. Recurrent bleeding from esophageal ulcers carries an extremely high mortality rate, particularly in patients with advanced stage cirrhosis. Therefore, how to promote esophageal ulcer healing and prevent ulcer rebleeding is an important clinical issue.\n\nProton pump inhibitors (PPIs) are the primary drugs for preventing and treating gastric ulcers, but clinical evidence for their role in preventing post-ligation esophageal ulcers is insufficient. Sucralfate, a complex of aluminum hydroxide and sucrose octa sulfate, can bind to the wound base. This protective barrier can prevent the wound from further environmental injury. Sucralfate has been widely used for wounds and ulcer treatment, e.g., skin wounds, oral ulcers, and peptic ulcers. Our recent clinical trial also proved topical sucralfate can prevent postpolypectomy bleeding. Therefore, this study aimed to investigate whether the topical administration of sucralfate after standard endoscopic hemostasis can promote the esophageal ulcer healing and reduce the rebleeding event.",[25],"Ulcer Healing",[27,28,29],"Esophageal varices","Post-ligation ulcer","Sucralfate","NOT_YET_RECRUITING","2026-06-25",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":33,"type":19},{"date":37,"type":19},"2027-12-31",{"name":39,"class":40},"National Cheng-Kung University Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":52,"conditions":53,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100458581","examining-the-effectiveness-of-dermgen-in-the-treatment-of-diabetic-foot-ulcers-in-first-nations-people-100458581","NCT05251480","Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People","Examining the Effectiveness of DermGEN™ Versus Standard of Care in the Treatment of Diabetic Foot Ulcers in First Nations People Living in Northwestern Ontario Communities","Inclusion Criteria:\n\n* Participant and social support (e.g., family, caregiver) ready and willing to participate and comply with follow-up regime\n* Participant willing to be involved in self-care (e.g., keep dressing dry at home) required during treatment\n* Participant willing to wear Total Contact Cast (TCC) for wound off-loading during treatment\n* Participant or legal representative has read and signed the informed consent form\n* Documented stable Type I or II diabetes (HbA1C between 5.0 to 10 mmol\u002FL within 1 month prior to Day 0)\n* Ulcer has been present for a minimum of 2 weeks as of Day 0\n* Ulcer area is ≥2 cm2 prior to debridement at Day 0 of study\n* Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule\n* Ulcer is free of dead tissue and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0\n* Adequate perfusion to the extremity determined by at least one of the following:\n\nPalpable pedal pulses, Transcutaneous oxygen measurement at the dorsum of the foot ≥30 mm Hg, Ankle-brachial index ranging from 0.8 to 1.2, At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries\n\nExclusion Criteria:\n\n* The individual has any condition that seriously compromises their capacity to provide consent and answers questions related to this study.\n* Untreated infection of soft tissue or bone and\u002For autoimmune connective tissue disorders\n* Ulcer is over Charcot deformity (joints deformity of foot and ankle common in people with diabetes)\n* Body mass index ≥50 kg\u002Fm2\n* Ulcer is not classified as diabetes-related\n* Ulcer has tunnels or sinus tracts that cannot be completely debrided\n* Medical condition(s) that in the investigators' opinion make the patient inappropriate for study (e.g active liver disease)\n* Presence of malignant disease not in remission for 5 years or more\n* The individual is undergoing chemotherapy\u002Fradiation therapy\n* The individual received radiation therapy within 30 days of Day 0 of study\n* The individual is taking an immunosuppressant medication (e.g., corticosteroids, immunosuppression or cytotoxic agents), or is anticipated to require such agents during study\n* Presence of acute or chronic hepatitis, liver disease, anemia, serum albumin \\\u003C2.0 gm\u002FdL, or has alkaline phosphatase or LDH at twice the normal upper limit\n* Obvious clinical signs and symptoms of ongoing tissue infection (i.e., cellulitis) or bone infection (i.e., osteomyelitis)\n* Female individuals are pregnant at time or intend to get pregnant during study time\n* The individual has known allergies to antibiotics, such as penicillin and streptomycin\n* The individual is an active smoker (smoke one or more cigarette a day)\n* The individual has a history of a bleeding disorder or is taking blood thinner medication","80 Years",{"count":50,"type":19},120,[22],"The study will examine the effectiveness of a decellularized dermal matrix (i.e., DermGEN™) in improving wound healing, quality of life and associated costs of treatment of DFUs in First Nations people living in the Northwestern Ontario Communities. First Nations people with active diabetic foot (DFU) ulcer attending a wound care clinic located at the Rainy River district office. An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.",[54,55,25,56,57,58,59,60],"Diabetes Mellitus","Ulcer Foot","Diabetic Foot Ulcer","Non-healing Wound","Wound of Skin","Wound; Foot","Tissue Injury",[62,56,57,63,64,65,66,67,68,69],"Diabetic Ulcer","Tissue Engineering","Regenerative Medicine","Decellularized Matrix","Acellular Dermal Matrix","Tissue Allograft","Indigenous Healing","Advanced Wound Care","2024-07-02",{"date":72,"type":34},"2024-07-03",{"date":74,"type":19},"2024-12-30",{"date":76,"type":19},"2026-12-01",{"name":78,"class":79},"DeCell Technologies Inc.","INDUSTRY",1]